BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25557962)

  • 21. Impact of CYP1A1, GSTP1 and XRCC1 genes polymorphisms on toxicity and response to chemotherapy in childhood acute lymphoblastic leukemia.
    Abo-Bakr A; Mossallam G; El Azhary N; Hafez H; Badawy R
    J Egypt Natl Canc Inst; 2017 Sep; 29(3):127-133. PubMed ID: 28844589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
    Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
    Haematologica; 1997; 82(5 Suppl):19-22. PubMed ID: 9402749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
    Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
    J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia.
    Kakihara T; Fukuda T; Tanaka A; Emura I; Kishi K; Asami K; Uchiyama M
    Leuk Lymphoma; 1998 Oct; 31(3-4):405-9. PubMed ID: 9869205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract]   [Full Text] [Related]  

  • 29. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
    Kornblau SM; Cortes-Franco J; Estey E
    Leukemia; 1993 Mar; 7(3):378-83. PubMed ID: 8445943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
    Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
    Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
    Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
    Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study.
    Wan H; Zhu J; Chen F; Xiao F; Huang H; Han X; Zhong L; Zhong H; Xu L; Ni B; Zhong J
    J Exp Clin Cancer Res; 2014 Nov; 33(1):90. PubMed ID: 25398670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
    Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
    Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
    Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
    Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.
    Koehl U; Hollatz G; Rohrbach E; Visschedyk K; Cinatl J; Kornhuber B; Kreuter J; Mutschler E; Schwabe D
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):467-77. PubMed ID: 17171362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
    Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
    Estlin EJ; Yule SM; Lowis SP
    Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
    Yang JJ; Cheng C; Yang W; Pei D; Cao X; Fan Y; Pounds SB; Neale G; Treviño LR; French D; Campana D; Downing JR; Evans WE; Pui CH; Devidas M; Bowman WP; Camitta BM; Willman CL; Davies SM; Borowitz MJ; Carroll WL; Hunger SP; Relling MV
    JAMA; 2009 Jan; 301(4):393-403. PubMed ID: 19176441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thalidomide increases in vitro sensitivity of childhood acute lymphoblastic leukemia cells to prednisolone and cytarabine.
    Czyzewski K; Zaborowska A; Styczyński J
    Arch Immunol Ther Exp (Warsz); 2006; 54(5):341-5. PubMed ID: 17031469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
    Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
    BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.